Stocklytics Platform
APRE
Aprea Therapeutics
APRE44
$3.25arrow_drop_down7.76%-$0.26
Penny Stock
APRE
APRE44

$3.25

arrow_drop_down7.76%

Performance History

Chart placeholder
Key Stats
Open$3.28
Prev. Close$3.35
EPS-2.80
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$18.19M
PE Ratio-
LOWHIGH
Day Range3.25
3.50
52 Week Range2.25
8.84
Ratios
Revenue-
EBITDA Margin %-
EPS-2.80

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

About Aprea Therapeutics (APRE)

Aprea Therapeutics Inc (APRE) is a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics. The company's lead product candidate is eprenetapopt (APR-246), a small molecule drug candidate that is being evaluated in clinical trials for the potential treatment of p53 mutant cancers. The p53 protein is a key regulator of cell cycle and apoptosis, and mutations in the p53 gene are found in a wide range of tumor types. Aprea is targeting patients with p53 mutant cancers who currently have limited treatment options.
The stock price history of Aprea Therapeutics Inc (APRE) shows that the company went public on the Nasdaq Global Market on December 6, 2019, with an initial public offering (IPO) price of $15 per share. The stock price has experienced fluctuations since its IPO, with highs and lows reflecting market conditions and investor sentiment. As of the latest available data, the stock is trading at $25 per share.
Websitecall_made
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Oren Gilad Ph.D.
Headquarters
Doylestown
Employees
9
Exchange
NASDAQ
add Aprea Therapeutics to watchlist

Keep an eye on Aprea Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Aprea Therapeutics 's (APRE) price per share?

The current price per share for Aprea Therapeutics (APRE) is $3.25. The stock has seen a price change of -$0.26 recently, indicating a -7.76% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Aprea Therapeutics (APRE)?

For Aprea Therapeutics (APRE), the 52-week high is $8.85, which is 172.22% from the current price. The 52-week low is $2.25, the current price is 44.44% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Aprea Therapeutics (APRE) a growth stock?

Aprea Therapeutics (APRE) has shown an average price growth of -6.65% over the past three years. It has received a score of 3 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Aprea Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Aprea Therapeutics (APRE) stock price performance year to date (YTD)?

As of the latest data, Aprea Therapeutics (APRE) has a year-to-date price change of -35%. Over the past month, the stock has experienced a price change of -7.14%. Over the last three months, the change has been -14.47%. Over the past six months, the figure is -41.86%. Looking at a longer horizon, the five-year price change stands at -99.45%.
help

Is Aprea Therapeutics (APRE) a profitable company?

Aprea Therapeutics (APRE) has a net income of -$14.29M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -685.03% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $576.18K. Operating income is noted at -$15.47M. Furthermore, the EBITDA is -$14.18M.
help

What is the market capitalization of Aprea Therapeutics (APRE)?

Aprea Therapeutics (APRE) has a market capitalization of $17.66M. The average daily trading volume is 3.32, indicating the stock's liquidity and investor engagement.

News

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
CALENDAR OF EVENTS
CONFERENCE CALLS/ WEBCASTS
Jun 21, 2024

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024

Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
PRODUCT / SERVICES ANNOUNCEMENT
CLINICAL STUDY
Jun 17, 2024

Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051

Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
HEALTH
REGULATORY INFORMATION
CLINICAL STUDY
May 28, 2024

Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial

Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
CALENDAR OF EVENTS
May 13, 2024

Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference

Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
DIRECTORS AND OFFICERS
May 2, 2024

Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
CALENDAR OF EVENTS
CLINICAL STUDY
Apr 10, 2024

Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level